| 51 |
20976259 | Modulation of the ribonucleotide reductase-antimetabolite drug interaction in cancer cell lines. | 2010 Sep 28 |
2 |
| 52 |
19887545 | Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. | 2009 Nov |
1 |
| 53 |
18690840 | FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer. | 2008 Aug |
1 |
| 54 |
21479491 | Role of ASC in hypoxia-mediated cell death in pancreatic cancer. | 2008 Nov-Dec |
1 |
| 55 |
17671697 | Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis. | 2007 Sep |
2 |
| 56 |
16505115 | c-Abl-independent p73 stabilization during gemcitabine- or 4'-thio-beta-D-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells. | 2006 Feb |
11 |
| 57 |
16690105 | Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines. | 2006 Nov |
1 |
| 58 |
16820892 | Growth inhibition and apoptosis induction in ovarian cancer cells. | 2006 Aug |
1 |
| 59 |
17079445 | Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy. | 2006 Nov 1 |
2 |
| 60 |
16006755 | Enhancement of gemcitabine-induced apoptosis by restoration of p53 function in human pancreatic tumors. | 2005 |
3 |
| 61 |
16238441 | Unraveling the mechanism of radiosensitization by gemcitabine: the role of TP53. | 2005 Nov |
1 |
| 62 |
15199526 | Promising combination therapies with gemcitabine. | 2004 Apr |
2 |
| 63 |
15464472 | Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. | 2004 Oct |
1 |
| 64 |
15476743 | Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. | 2004 Oct 19 |
2 |
| 65 |
12597983 | Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells. | 2003 Feb |
1 |
| 66 |
12684687 | The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. | 2003 May |
1 |
| 67 |
12811511 | Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1. | 2003 Sep |
1 |
| 68 |
11802204 | Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. | 2002 Feb 1 |
6 |
| 69 |
11458051 | Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer. | 2001 Aug |
2 |
| 70 |
11489842 | Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breast carcinoma cell lines. | 2001 Aug |
2 |
| 71 |
11585734 | Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction. | 2001 Oct 1 |
1 |
| 72 |
11751391 | Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage. | 2001 Dec 15 |
6 |
| 73 |
10803919 | The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization. | 2000 |
6 |
| 74 |
10811472 | Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (Ad5CMV-p53) in human pancreatic cancer. | 2000 Apr |
1 |
| 75 |
11085531 | The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine. | 2000 Nov 1 |
2 |
| 76 |
10341297 | Induction of growth inhibition and apoptosis in pancreatic cancer cells by auristatin-PE and gemcitabine. | 1999 Jun |
1 |
| 77 |
9772293 | Cell cycle arrest in ovarian cancer cell lines does not depend on p53 status upon treatment with cytostatic drugs. | 1998 Nov |
1 |